Platform Biotech Models Attract Investor Interest as Drug-Delivery Market Poised to Reach $410 Billion

As the cost of oncology drug development continues to rise and regulatory approvals become more challenging, biotechnology companies are shifting focus toward extracting greater value from existing therapies through advanced delivery technologies rather than relying solely on new compound discovery. The global drug-delivery market is projected to reach $410 billion, driving investor interest in platform-based models that leverage nanotechnology, intravenous reformulation, and pharmacokinetic engineering to improve bioavailability, systemic exposure, tolerability, and dosing reliability of established cancer medicines.

Oncotelic Therapeutics Inc. (OTCQB: OTLC) is emerging as a key player in this space, advancing its Sapu003 program and Deciparticle platform as part of a broader industry move toward scalable nanotechnology-driven drug delivery and AI-enhanced biomedical infrastructure. The company’s strategy centers on platform technologies that can be applied across multiple therapeutic areas, including oncology and rare diseases, rather than depending on a single drug candidate. This approach is shared by other firms such as CytoDyn Inc. (OTCQB: CYDY), Revolution Medicines Inc. (NASDAQ: RVMD), Moderna Inc. (NASDAQ: MRNA), and Sarepta Therapeutics Inc. (NASDAQ: SRPT), all of which are developing scalable biotechnology platforms to support multiple therapeutic programs.

The emphasis on platform technologies reflects a recognition that drug delivery innovations can significantly enhance the performance of existing drugs, potentially reducing development risks and costs. For investors, platform-based models offer the allure of multiple shots on goal, as a successful platform can be adapted for various indications, spreading risk and increasing the potential for returns. This is particularly relevant in oncology, where drug development expenses have soared and the failure rate for novel compounds remains high.

Oncotelic’s Deciparticle platform is designed to improve the delivery of anticancer agents, aiming to enhance their efficacy and safety profiles. The company is also leveraging artificial intelligence to optimize its platform and identify new applications. As the drug-delivery market expands, companies with robust platform technologies are well-positioned to capture a significant share of the growing demand for improved therapeutic delivery systems.

The trend toward platform-based biotech models is reshaping the investment landscape, with investors increasingly valuing companies that have versatile technology platforms over those with single-product pipelines. This shift is expected to accelerate as the drug-delivery market continues to grow, driven by the need for more effective and patient-friendly treatments. With the global market on track to reach $410 billion, platform biotech firms are drawing heightened interest from both institutional and retail investors seeking exposure to innovative drug-delivery solutions.

This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp. The source URL for this press release is Platform Biotech Models Attract Investor Interest as Drug-Delivery Market Poised to Reach $410 Billion.

The post Platform Biotech Models Attract Investor Interest as Drug-Delivery Market Poised to Reach $410 Billion appeared first on citybuzz.